Pacira BioSciences (NASDAQ:PCRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Pacira BioSciences (NASDAQ:PCRX – Get Rating) in a research note published on Thursday morning. The firm issued a hold rating on the stock.

Other research analysts have also issued reports about the company. Truist Financial decreased their price objective on Pacira BioSciences from $68.00 to $63.00 in a research report on Wednesday, January 18th. Royal Bank of Canada cut their price target on Pacira BioSciences from $80.00 to $76.00 and set an outperform rating on the stock in a research note on Wednesday, March 1st. HC Wainwright increased their price target on Pacira BioSciences from $69.00 to $71.00 and gave the company a buy rating in a research note on Wednesday, March 1st. Wedbush reissued an outperform rating and issued a $60.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 31st. Finally, Cowen cut their price target on Pacira BioSciences from $54.00 to $50.00 in a research note on Wednesday, December 14th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $64.36.

Pacira BioSciences Stock Down 4.8 %

Shares of PCRX opened at $39.49 on Thursday. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 127.39 and a beta of 0.77. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.72 and a current ratio of 3.37. The business’s fifty day moving average price is $39.88 and its two-hundred day moving average price is $46.00. Pacira BioSciences has a 52 week low of $35.35 and a 52 week high of $82.16.

Pacira BioSciences (NASDAQ:PCRX – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.11). The firm had revenue of $171.96 million during the quarter, compared to the consensus estimate of $174.12 million. Pacira BioSciences had a net margin of 2.39% and a return on equity of 11.09%. On average, analysts predict that Pacira BioSciences will post 2.73 earnings per share for the current year.

Institutional Trading of Pacira BioSciences

Hedge funds have recently added to or reduced their stakes in the business. Neo Ivy Capital Management acquired a new stake in Pacira BioSciences during the 2nd quarter worth $44,000. Financial Freedom LLC acquired a new stake in Pacira BioSciences during the 4th quarter worth $33,000. Quadrant Capital Group LLC raised its stake in Pacira BioSciences by 380.8% during the 3rd quarter. Quadrant Capital Group LLC now owns 875 shares of the company’s stock worth $47,000 after buying an additional 693 shares during the period. ICA Group Wealth Management LLC acquired a new stake in Pacira BioSciences during the 4th quarter worth $35,000. Finally, Dark Forest Capital Management LP raised its stake in Pacira BioSciences by 92,300.0% during the 4th quarter. Dark Forest Capital Management LP now owns 924 shares of the company’s stock worth $36,000 after buying an additional 923 shares during the period.

About Pacira BioSciences

(Get Rating)

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.